Fengshi leads $45m Series D for China cancer diagnosis player
Singlera Genomics, a Shanghai-based cancer diagnostics specialist, has raised an extended Series B round of CNY 300m (USD 45m) led by Fengshi Investment Management.
Other investors include Galaxy Huiyuan Investment, Huachen Meijing Equity Investment, Wuxi Guojing Investment Management, Unifortune Investment, Hubei Baiside Private Fund Management, and Shanghai Junci…
Latest News
[China's Insilico Medicine gets $60m Series D]
Insilico Medicine, a China-based artificial intelligence (AI)-driven drug discovery company, has raised a USD 60 million Series D round.
Fengshi leads $45m Series D for China cancer diagnosis player comes via ChinaTechNews.com.
